Categories: Uncategorized

USFDA nod to Zydus for production of Fluphenazine Hydrochloride

Zydus Cadila has received final approval from the USFDA to market Fluphenazine Hydrochloride Tablets in the strengths of 1 mg, 2.5 mg, 5 mg, and 10 mg (US RLD: Prolixin Tablets). This medication is used to treat symptoms of a certain type of mental/mood condition (schizophrenia). Fluphenazine belongs to a class of medications called phenothiazines and is also referred to as a neuroleptic.

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 318 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Medically Speaking Team

Recent Posts

THE HIDDEN CHALLENGE OF WEIGHT LOSS: HOW FAT CELLS “REMEMBER” OBESITY

Losing weight is a significant milestone, but for many, the bigger battle lies in keeping…

19 hours ago

LINDT CHOCOLATE CONTROVERSY: HEAVY METALS DISCOVERED IN POPULAR BRAND’S PRODUCTS

In recent months, a growing controversy has surfaced regarding the presence of heavy metals—specifically lead…

20 hours ago

THE SURPRISING BENEFITS OF VITAMIN B3 IN LOWERING DEATH RISK AND IMPROVING HEART HEALTH

A new study published in Scientific Reports has shed light on the potential benefits of dietary…

20 hours ago

WOMEN’S HEALTH: HOW EXCESS ZINC CAN DISRUPT MENSTRUAL CYCLE AND FERTILITY

Zinc is an essential mineral that plays a crucial role in maintaining overall health. Known…

22 hours ago

AIIMS- LED TRIAL FINDS OPTIMAL DRUG COMBINATION FOR HYPERTENSION PATIENTS

A groundbreaking clinical trial, spearheaded by a team of Indian and international experts, has shed…

22 hours ago

LINK BETWEEN COVID-19 INFECTION AND CANCER REGRESSION UNCOVERED IN A GROUNDBREAKING DISCOVERY

In an unprecedented discovery, scientists have uncovered a surprising connection between COVID-19 infections and the…

24 hours ago